Sana Biotechnology

### Executive Summary Sana Biotechnology raised $501.8M in a Regulation D private placement, signaling strong institutional confidence in synthetic biology and intracellular mRNA delivery. The first sale date of 2025-10-12 indicates the offering closed over 7 months ago, with no subsequent amendments filed as of today. ### Investor Edge Monitor for any D/A amendments or public announcements from Shield Capital or Founders Fund regarding follow-on investments or clinical trial updates, as the large raise likely funds late-stage preclinical or early clinical work. ### Sector capital positioning This $501.8M raise is one of the largest private synthetic biology rounds in recent years, reinforcing a capital flow trend toward mRNA delivery platforms and cell engineering. ### Convergence Signals No public signals (patents, contracts, legislation) are evident from the filing data. The absence of a ticker and D/A amendments suggests the company remains private and has not yet disclosed additional milestones. ### Key Takeaways - Sana Biotechnology raised $501.8M in a private placement, one of the largest in synthetic biology. - First sale date of 2025-10-12 and no D/A amendments suggest the offering closed without subsequent changes. - Related persons include Shield Capital and Founders Fund, indicating top-tier VC backing. ### Risk Indicators & Flags No D/A amendments filed, which is typical for a completed initial placement. No regulatory concerns flagged in the filing, but the large amount in a capital-intensive sector warrants monitoring for future dilution or clinical setbacks. ### Verification & References Filing is a Form D (initial notice) with SEC accession 0001702600-24-20207, available at the provided SEC URL. First sale date 2025-10-12, capital raised $501.8M. Related persons are Shield Capital and Founders Fund as officers/directors.